JP2008510468A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008510468A5 JP2008510468A5 JP2007528061A JP2007528061A JP2008510468A5 JP 2008510468 A5 JP2008510468 A5 JP 2008510468A5 JP 2007528061 A JP2007528061 A JP 2007528061A JP 2007528061 A JP2007528061 A JP 2007528061A JP 2008510468 A5 JP2008510468 A5 JP 2008510468A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- polypeptide
- acid sequence
- arginine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 58
- 108090000765 processed proteins & peptides Proteins 0.000 claims 58
- 102000004196 processed proteins & peptides Human genes 0.000 claims 58
- 235000001014 amino acid Nutrition 0.000 claims 49
- 150000001413 amino acids Chemical class 0.000 claims 46
- 125000003275 alpha amino acid group Chemical group 0.000 claims 33
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 17
- 239000004475 Arginine Substances 0.000 claims 16
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 7
- 125000000539 amino acid group Chemical group 0.000 claims 7
- 235000013922 glutamic acid Nutrition 0.000 claims 7
- 239000004220 glutamic acid Substances 0.000 claims 7
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 7
- 241000124008 Mammalia Species 0.000 claims 6
- 239000000539 dimer Substances 0.000 claims 6
- 108020001507 fusion proteins Proteins 0.000 claims 6
- 102000037865 fusion proteins Human genes 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 239000013604 expression vector Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 108091008551 RET receptors Proteins 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000000653 nervous system Anatomy 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60282504P | 2004-08-19 | 2004-08-19 | |
| US60/602,825 | 2004-08-19 | ||
| US69406705P | 2005-06-24 | 2005-06-24 | |
| US60/694,067 | 2005-06-24 | ||
| PCT/US2005/029637 WO2006023781A2 (en) | 2004-08-19 | 2005-08-18 | Neublastin variants |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011108760A Division JP2011155987A (ja) | 2004-08-19 | 2011-05-13 | ニューブラスチン（Ｎｅｕｂｌａｓｔｉｎ）変異体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008510468A JP2008510468A (ja) | 2008-04-10 |
| JP2008510468A5 true JP2008510468A5 (enExample) | 2008-06-26 |
| JP4852545B2 JP4852545B2 (ja) | 2012-01-11 |
Family
ID=35968235
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007528061A Expired - Fee Related JP4852545B2 (ja) | 2004-08-19 | 2005-08-18 | ニューブラスチン（Ｎｅｕｂｌａｓｔｉｎ）変異体 |
| JP2011108760A Withdrawn JP2011155987A (ja) | 2004-08-19 | 2011-05-13 | ニューブラスチン（Ｎｅｕｂｌａｓｔｉｎ）変異体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011108760A Withdrawn JP2011155987A (ja) | 2004-08-19 | 2011-05-13 | ニューブラスチン（Ｎｅｕｂｌａｓｔｉｎ）変異体 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US8263553B2 (enExample) |
| EP (3) | EP2335713A3 (enExample) |
| JP (2) | JP4852545B2 (enExample) |
| KR (2) | KR20110126732A (enExample) |
| CN (1) | CN102924585A (enExample) |
| AT (1) | ATE474586T1 (enExample) |
| AU (1) | AU2005277226B2 (enExample) |
| BR (1) | BRPI0514534A (enExample) |
| CA (1) | CA2577755C (enExample) |
| CY (1) | CY1111136T1 (enExample) |
| DE (1) | DE602005022457D1 (enExample) |
| DK (1) | DK1786454T3 (enExample) |
| EA (1) | EA013565B1 (enExample) |
| GE (1) | GEP20115196B (enExample) |
| HR (1) | HRP20100474T1 (enExample) |
| IL (2) | IL181311A (enExample) |
| MX (1) | MX2007002029A (enExample) |
| NO (1) | NO20071449L (enExample) |
| NZ (1) | NZ553431A (enExample) |
| PL (1) | PL1786454T3 (enExample) |
| PT (1) | PT1786454E (enExample) |
| RS (1) | RS51453B (enExample) |
| SI (1) | SI1786454T1 (enExample) |
| UA (1) | UA92590C2 (enExample) |
| WO (1) | WO2006023781A2 (enExample) |
| ZA (1) | ZA200701395B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7442370B2 (en) | 2001-02-01 | 2008-10-28 | Biogen Idec Ma Inc. | Polymer conjugates of mutated neublastin |
| US7276580B2 (en) | 2001-03-12 | 2007-10-02 | Biogen Idec Ma Inc. | Neurotrophic factors |
| JP4571776B2 (ja) * | 2002-11-05 | 2010-10-27 | Ｊｘ日鉱日石エネルギー株式会社 | 潤滑油組成物 |
| ATE433759T1 (de) | 2003-04-18 | 2009-07-15 | Biogen Idec Inc | Polymerkonjugiertes glycosiliertes neublastin |
| JP4959566B2 (ja) * | 2004-08-19 | 2012-06-27 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | トランスホーミング増殖因子βファミリータンパク質の折りたたみ |
| EP2335713A3 (en) | 2004-08-19 | 2011-11-02 | Biogen Idec MA Inc. | Neublastin variants |
| TWI501774B (zh) | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | 神經性病症之治療 |
| WO2007103182A2 (en) * | 2006-03-01 | 2007-09-13 | Biogen Idec Ma Inc. | Compostions and methods for administering gdnf ligand family proteins |
| JP5583005B2 (ja) * | 2007-05-01 | 2014-09-03 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 血管新生を増大させるための組成物および方法 |
| WO2009020964A2 (en) * | 2007-08-08 | 2009-02-12 | Biogen Idec Ma Inc. | Anti-neublastin antibodies and uses thereof |
| WO2015042580A1 (en) | 2013-09-23 | 2015-03-26 | Biogen Idec Ma Inc. | Compositions and methods for treatment of neuropathic pain |
| WO2016022800A1 (en) | 2014-08-07 | 2016-02-11 | Biogen Ma Inc. | Characterization of cystine knot superfamily proteins |
| CA3124660A1 (en) * | 2018-12-21 | 2020-06-25 | Gloriana Therapeutics Sarl | Mammalian cell culture-produced neublastin antibodies |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4352883A (en) | 1979-03-28 | 1982-10-05 | Damon Corporation | Encapsulation of biological material |
| US4353888A (en) | 1980-12-23 | 1982-10-12 | Sefton Michael V | Encapsulation of live animal cells |
| US4407957A (en) | 1981-03-13 | 1983-10-04 | Damon Corporation | Reversible microencapsulation of a core material |
| US5525464A (en) | 1987-04-01 | 1996-06-11 | Hyseq, Inc. | Method of sequencing by hybridization of oligonucleotide probes |
| US4883666A (en) | 1987-04-29 | 1989-11-28 | Massachusetts Institute Of Technology | Controlled drug delivery system for treatment of neural disorders |
| US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
| DE3829752A1 (de) | 1988-09-01 | 1990-03-22 | Akzo Gmbh | Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration |
| DE3829766A1 (de) | 1988-09-01 | 1990-03-22 | Akzo Gmbh | Verfahren zur herstellung von membranen |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5194596A (en) | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
| US5350836A (en) | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| GB8927546D0 (en) | 1989-12-06 | 1990-02-07 | Ciba Geigy | Process for the production of biologically active tgf-beta |
| US5084350A (en) | 1990-02-16 | 1992-01-28 | The Royal Institution For The Advance Of Learning (Mcgill University) | Method for encapsulating biologically active material including cells |
| US5618531A (en) | 1990-10-19 | 1997-04-08 | New York University | Method for increasing the viability of cells which are administered to the brain or spinal cord |
| EP0585368B1 (en) | 1991-04-25 | 1997-08-06 | Brown University Research Foundation | Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products |
| ES2284226T3 (es) | 1991-07-02 | 2007-11-01 | Nektar Therapeutics | Dispositivo para proporcionar medicamentos en aerosol. |
| ATE275197T1 (de) | 1991-09-20 | 2004-09-15 | Amgen Inc | Glial neurotrophe faktor |
| US5939524A (en) | 1991-12-09 | 1999-08-17 | The Scripps Research Institute | Platelet GPIII P1A1 and P1A2 epitopes, their preparation and use |
| US5414135A (en) | 1991-12-30 | 1995-05-09 | Sterling Winthrop Inc. | Vinyl sulfone coupling of polyoxyalkylenes to proteins |
| US5785049A (en) | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
| DK0679088T3 (da) | 1992-09-29 | 2002-10-28 | Inhale Therapeutic Syst | Pulmonal levering af aktive fragmenter af parathyreoideaea hormon |
| US5349056A (en) | 1992-10-09 | 1994-09-20 | Regeneron Pharmaceuticals | Modified ciliary neurotrophic factors |
| CA2092271C (en) | 1993-03-09 | 2009-10-13 | Eddie Reed | Use of g-csf for treating taxol side-effects |
| EP0802800B1 (en) | 1993-08-12 | 2002-06-12 | Neurotech S.A. | Biocompatible immunoisolatory capsules containing genetically altered cells for the delivery of biologically active molecules |
| DE4339605A1 (de) | 1993-11-20 | 1995-05-24 | Beiersdorf Ag | Desodorierende Wirkstoffkombinationen auf der Basis von alpha, omega-Alkandicarbonsäuren und Fettsäurepartialglyceriden |
| US5834029A (en) | 1994-07-20 | 1998-11-10 | Cytotherapeutics, Inc. | Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US5795716A (en) | 1994-10-21 | 1998-08-18 | Chee; Mark S. | Computer-aided visualization and analysis system for sequence evaluation |
| US5770577A (en) | 1994-11-14 | 1998-06-23 | Amgen Inc. | BDNF and NT-3 polypeptides selectively linked to polyethylene glycol |
| US5780014A (en) | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
| US5654007A (en) | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
| US5739307A (en) | 1995-08-28 | 1998-04-14 | Washington University | Polynucleotide encoding neurturin neurotrophic factor |
| US5733729A (en) | 1995-09-14 | 1998-03-31 | Affymetrix, Inc. | Computer-aided probability base calling for arrays of nucleic acid probes on chips |
| US6063757A (en) | 1995-11-29 | 2000-05-16 | Urso; Richard G. | Wound treatment method with nerve growth factor |
| US5641749A (en) | 1995-11-29 | 1997-06-24 | Amgen Inc. | Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product |
| EP0943690B1 (en) | 1995-12-21 | 2006-11-29 | Ajinomoto Co., Inc. | Method for refolding human activin a |
| US6299895B1 (en) | 1997-03-24 | 2001-10-09 | Neurotech S.A. | Device and method for treating ophthalmic diseases |
| US6677135B1 (en) | 1996-05-08 | 2004-01-13 | Biogen, Inc. | Ret ligand (RetL) for stimulating neutral and renal growth |
| US5754524A (en) | 1996-08-30 | 1998-05-19 | Wark; Barry J. | Computerized method and system for analysis of an electrophoresis gel test |
| US6083725A (en) | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
| AU736670B2 (en) | 1996-09-26 | 2001-08-02 | Medical Research Council | Chaperone fragments |
| KR100195886B1 (ko) | 1996-11-01 | 1999-06-15 | 김상조 | 당뇨병 치료용 의약조성물 |
| US6653098B1 (en) | 1998-02-23 | 2003-11-25 | G. D. Searle & Co. | Method of producing mouse and human endostatin |
| US6593133B1 (en) | 1998-07-06 | 2003-07-15 | Nsgene A/S | Neurotrophic factors |
| US20020055467A1 (en) | 1998-07-06 | 2002-05-09 | Johansen Teit E. | Novel neurotrophic factors |
| HK1045528B (zh) | 1998-07-14 | 2006-10-27 | 詹森药业有限公司 | 神经营养生长因子 |
| US7067473B1 (en) | 1998-07-14 | 2006-06-27 | Janssen Pharmaceutica N.V. | Neurotrophic growth factor |
| AU778998B2 (en) | 1998-09-22 | 2004-12-23 | University Of Maryland At Baltimore | Cystine knot growth factor mutants |
| US6284540B1 (en) * | 1998-09-29 | 2001-09-04 | Washington University | Artemin, a novel neurotrophic factor |
| US6361771B1 (en) | 1999-04-06 | 2002-03-26 | Neurotech S.A. | ARPE-19 as a platform cell line for encapsulated cell-based delivery |
| EP1175235A1 (en) | 1999-04-22 | 2002-01-30 | Eidgenossisch Technische Hochschule Zurich | Modified protein matrices |
| PT1223966E (pt) | 1999-10-29 | 2003-09-30 | Biopharm Ges Biotechn Entwickl | Utilizacao do gdnf para tratamento de defeitos na cornea |
| CA2327208A1 (en) | 2000-11-30 | 2002-05-30 | The Government Of The United States Of America | Methods of increasing distribution of therapeutic agents |
| NZ526610A (en) | 2000-12-22 | 2009-08-28 | Genentech Inc | New use of artemin, a member of the GDNF ligand family |
| US7442370B2 (en) | 2001-02-01 | 2008-10-28 | Biogen Idec Ma Inc. | Polymer conjugates of mutated neublastin |
| SK288123B6 (sk) * | 2001-02-01 | 2013-09-03 | Biogen Idec Ma Inc. | Polymer conjugates of neublastin and methods of using same |
| US7276580B2 (en) | 2001-03-12 | 2007-10-02 | Biogen Idec Ma Inc. | Neurotrophic factors |
| US20040077543A1 (en) | 2001-03-28 | 2004-04-22 | Sah Dinah W. Y. | Treatment using neublastin polypeptides |
| AU2002250203B2 (en) * | 2001-03-28 | 2006-08-10 | Biogen Ma Inc. | Use of neublastin polypeptides for treating neuropathic pain |
| EP1389121B1 (en) | 2001-04-24 | 2012-02-22 | Purdue Research Foundation | Method and compositions for treating mammalian nerve tissue injuries |
| US7135334B2 (en) | 2001-06-20 | 2006-11-14 | Genentech, Inc. | PRO20044 nucleic acids |
| US20040028613A1 (en) | 2001-06-25 | 2004-02-12 | Nastech Pharmaceutical Company Inc | Dopamine agonist formulations for enhanced central nervous system delivery |
| US7129085B2 (en) | 2001-10-11 | 2006-10-31 | Bristol-Myers Squibb Company | Polynucleotides encoding a human leucine-rich repeat domain containing protein, HLLRCR-1 |
| GB0205022D0 (en) | 2002-03-04 | 2002-04-17 | Univ Cambridge Tech | Materials and methods for the treatment of cns damage |
| JP4310608B2 (ja) | 2002-04-25 | 2009-08-12 | 東洋紡績株式会社 | Ｈｓｐ７０ファミリータンパク質基質結合ドメインフラグメントの利用方法 |
| ATE433759T1 (de) | 2003-04-18 | 2009-07-15 | Biogen Idec Inc | Polymerkonjugiertes glycosiliertes neublastin |
| RU2005138368A (ru) | 2003-06-10 | 2006-07-27 | ЭнЭсДЖЕНЕ А/С (DK) | Улучшенная секреция нейбластина |
| US7598059B2 (en) | 2003-10-02 | 2009-10-06 | Biogen Idec Ma Inc. | Neublastin expression constructs |
| WO2005072764A2 (en) | 2004-01-16 | 2005-08-11 | Novocell, Inc. | Fibrin-bound angiogenic factors to stimulate vascularization of transplant site of encapsulated cells |
| EP1784486B1 (en) | 2004-06-23 | 2011-10-05 | TissueGene, Inc. | Nerve regeneration |
| US7598356B2 (en) | 2004-07-08 | 2009-10-06 | Board of Regents of the University of Nebraska by and on behalf of the University of Nebraska Medical Center | Method for purifying a protein of the cystine-knot superfamily |
| JP4959566B2 (ja) | 2004-08-19 | 2012-06-27 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | トランスホーミング増殖因子βファミリータンパク質の折りたたみ |
| EP2335713A3 (en) | 2004-08-19 | 2011-11-02 | Biogen Idec MA Inc. | Neublastin variants |
| EP1937295A2 (en) | 2005-10-11 | 2008-07-02 | NS Gene A/S | Treatment of retinopathies using gfr 3 agonists |
| TWI501774B (zh) | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | 神經性病症之治療 |
| WO2007103182A2 (en) | 2006-03-01 | 2007-09-13 | Biogen Idec Ma Inc. | Compostions and methods for administering gdnf ligand family proteins |
| PT2019683T (pt) | 2006-04-25 | 2017-03-17 | Univ California | Administração de fatores de crescimento para o tratamento de distúrbios do snc |
| JP5583005B2 (ja) | 2007-05-01 | 2014-09-03 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 血管新生を増大させるための組成物および方法 |
-
2005
- 2005-08-18 EP EP10181609A patent/EP2335713A3/en not_active Withdrawn
- 2005-08-18 RS RSP-2010/0386A patent/RS51453B/sr unknown
- 2005-08-18 PL PL05789285T patent/PL1786454T3/pl unknown
- 2005-08-18 DE DE602005022457T patent/DE602005022457D1/de not_active Expired - Lifetime
- 2005-08-18 EP EP10170146.4A patent/EP2238983B1/en not_active Expired - Lifetime
- 2005-08-18 DK DK05789285.3T patent/DK1786454T3/da active
- 2005-08-18 WO PCT/US2005/029637 patent/WO2006023781A2/en not_active Ceased
- 2005-08-18 US US11/573,773 patent/US8263553B2/en not_active Expired - Fee Related
- 2005-08-18 NZ NZ553431A patent/NZ553431A/en not_active IP Right Cessation
- 2005-08-18 BR BRPI0514534-1A patent/BRPI0514534A/pt not_active IP Right Cessation
- 2005-08-18 EA EA200700460A patent/EA013565B1/ru not_active IP Right Cessation
- 2005-08-18 JP JP2007528061A patent/JP4852545B2/ja not_active Expired - Fee Related
- 2005-08-18 MX MX2007002029A patent/MX2007002029A/es active IP Right Grant
- 2005-08-18 KR KR1020117022960A patent/KR20110126732A/ko not_active Ceased
- 2005-08-18 AT AT05789285T patent/ATE474586T1/de active
- 2005-08-18 CA CA2577755A patent/CA2577755C/en not_active Expired - Fee Related
- 2005-08-18 GE GEAP20059928A patent/GEP20115196B/en unknown
- 2005-08-18 PT PT05789285T patent/PT1786454E/pt unknown
- 2005-08-18 KR KR1020077005926A patent/KR101215697B1/ko not_active Expired - Fee Related
- 2005-08-18 EP EP05789285A patent/EP1786454B1/en not_active Expired - Lifetime
- 2005-08-18 SI SI200531099T patent/SI1786454T1/sl unknown
- 2005-08-18 UA UAA200702764A patent/UA92590C2/uk unknown
- 2005-08-18 CN CN2012104009059A patent/CN102924585A/zh active Pending
- 2005-08-18 HR HR20100474T patent/HRP20100474T1/hr unknown
- 2005-08-18 AU AU2005277226A patent/AU2005277226B2/en not_active Ceased
-
2007
- 2007-02-13 IL IL181311A patent/IL181311A/en not_active IP Right Cessation
- 2007-02-16 ZA ZA2007/01395A patent/ZA200701395B/en unknown
- 2007-03-19 NO NO20071449A patent/NO20071449L/no not_active Application Discontinuation
-
2010
- 2010-04-19 IL IL205201A patent/IL205201A0/en unknown
- 2010-10-20 CY CY20101100936T patent/CY1111136T1/el unknown
-
2011
- 2011-05-13 JP JP2011108760A patent/JP2011155987A/ja not_active Withdrawn
-
2012
- 2012-07-03 US US13/541,302 patent/US20130096065A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008510468A5 (enExample) | ||
| JP2014510518A5 (enExample) | ||
| WO2008022759A3 (en) | Specific and high affinity binding proteins comprising modified sh3 domains of fyn kinase | |
| NZ627111A (en) | Variants of activin iib receptor polypeptides and uses thereof | |
| JP2018510622A5 (enExample) | ||
| JP2018515088A5 (enExample) | ||
| JP2017527272A5 (enExample) | ||
| HRP20200503T1 (hr) | Fuzijski proteini | |
| NZ590050A (en) | Fgf21 mutants and uses thereof | |
| JP2020500015A5 (enExample) | ||
| JP2020534352A5 (enExample) | ||
| NZ630484A (en) | Compositions and methods for treatment of metabolic disorders and diseases | |
| HRP20140616T1 (hr) | Peptidni analog oksintomodulina | |
| JP2016500250A5 (enExample) | ||
| NZ602634A (en) | Vista regulatory t cell mediator protein, vista binding agents and use thereof | |
| EP2476698A3 (en) | Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides | |
| JP2010529860A5 (enExample) | ||
| WO2009004315A8 (en) | Isolated peptides and uses thereof | |
| NZ606584A (en) | Binding proteins for hepcidin | |
| JP2017536098A5 (enExample) | ||
| WO2010013012A3 (en) | Hypothermia inducing polypeptides and uses thereof | |
| HRP20150664T1 (hr) | Antikancerogeni fuzijski protein | |
| JP2015504052A5 (enExample) | ||
| JP2019530441A5 (enExample) | ||
| JP2006506942A5 (enExample) |